Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-38.58	-25.5	-28.22	-18.49	-18.93
Depreciation & Amortization	0.24	0.17	0.16	0.15	0.09
Loss (Gain) From Sale of Assets	0	-0.02	0	0.01	-
Stock-Based Compensation	8.76	3.22	1.41	1.43	2.71
Other Operating Activities	1.74	-1.1	0.55	0.99	4.72
Change in Accounts Receivable	-0.43	-0.1	-0.1	0.23	0.15
Change in Accounts Payable	2.36	-0.71	0.58	1.32	-0.5
Change in Other Net Operating Assets	-2.64	-5.95	4.88	-0.04	0.05
Operating Cash Flow	-28.55	-29.99	-20.75	-14.4	-11.72
Capital Expenditures	-0.59	-0.1	-0.07	-0.24	-0.34
Sale of Property, Plant & Equipment	-	0.03	-	0	-
Investment in Securities	-	-	-	10.07	-7.11
Other Investing Activities	-	-	-	-	-3.97
Investing Cash Flow	-0.59	-0.08	-0.07	9.83	-11.42
Short-Term Debt Issued	-	-	-	-	0.08
Long-Term Debt Issued	-	-	-	-	10.08
Total Debt Issued	-	-	-	-	10.16
Long-Term Debt Repaid	-	-9.14	-0.08	-0.14	-0.46
Net Debt Issued (Repaid)	-	-9.14	-0.08	-0.14	9.69
Issuance of Common Stock	76.06	54.92	21.16	10.94	29.9
Financing Cash Flow	76.06	45.78	21.08	10.8	39.59
Foreign Exchange Rate Adjustments	0.54	-1.96	0.82	-0.51	-0.06
Net Cash Flow	47.46	13.76	1.08	5.73	16.39
Free Cash Flow	-29.14	-30.1	-20.82	-14.63	-12.06
Free Cash Flow Per Share	-0.73	-0.89	-0.86	-0.76	-0.97
Cash Interest Paid	-	0.39	0.6	0.33	0.46
Levered Free Cash Flow	-16.3	-20.95	-10.78	-8.72	-12.98
Unlevered Free Cash Flow	-16.3	-20.35	-10.05	-8.11	-12.37
Change in Working Capital	-0.71	-6.76	5.35	1.51	-0.3

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q